Hi Europe\ Event - N°65 en faveur de la marque Biofortis. cated to the analysis of microbiota, Ces BUs reçoivent le support d’une will act either as an internal supplier équipe d’experts en biostatistiques for clinical research projects in nutri- et bio-informatique. tion, or by directly serving pharma- ceutical industry (oncology, .. .), as A strategic study conducted in 2017- well as biotechs, cosmetics, veteri- 2018, with the support of Mérieux nary industries ... This comprehen- Nutrisciences, led to the setting sive and specialized service aims to up of a new organization aimed at become a leader in its fi eld. Finally, strengthening expertise in human the new “R & D” BU will follow and health, nutrition and microbiome. Three new business units (BU) are develop internal and collaborative born. The clinical “Clinical” BU, development projects in order to with 30 dedicated specialists and bring new operational solutions to 15 years of experience, aims to be the Biofortis brand. These BUs are an European leader in its fi eld, both supported by a team of experts in through organic and external growth. biostatistics and bioinformatics. ■ The detachment of a “Central Lab - Microbiome” BU, specifi cally dedi- Jennewein acquiert Arthus Mineralsprings 137 Jennewein acquires Arthus Mineralsprings La société allemande Jennewein in October that it has acquired Biotechnologie GmbH a annoncé the former facilities of Arthus l’acquisition des installations de Mineralspring Company in Bad fermentation de la société Arthus Hönningen (Germany) in order to Mineralspring à Bad Hönningen expand the production of human (Allemagne) a n d’accroître la milk oligosaccharides (HMOs). With production d’oligosaccharides the new plant, the company will be du lait maternel (HMO). (2 able to produce additional HMOs, '-fucosyllactose et lacto-N- expanding its current portfolio of néotétraose) et pour en inclure two products (2'-fucosyllactose cinq autres (3'-fucosyllactose, and lacto-N-neotetraose) to include difucosyllactose, lacto-N-tétraose, fi ve more (3'-fucosyllactose, 6'-sialyllactose et 3'-sialyllactose). difucosyllactose, lacto-N-tetraose, La nouvelle installation intégrée 6'-sialyllactose and 3'-sialyllactose). combinera la fermentation et The new integrated facility will la récupération, et produira combine fermentation and recovery, des produits HMO séchés and will yield spray-dried HMO par atomisation. Jennewein products. Jennewein Biotechnologie Biotechnologie projette de construire des lignes de productions distinctes plans to build separate production pour chaque sorte d’HMO produits. lines for the manufacture for each Avec des fermenteurs de plus de of the new HMO products. With 200 m3 chacun, l'usine deviendra fermenters of more than 200m3 l'une des plus grandes installations each, the new plant will become de fermentation en Europe centrale. one of the largest fermentation facilities in Central Europe. ■ The German company Jennewein Biotechnologie GmbH announced News on Functional & Health Ingredients \ N°65 \ October - November - December 2018 \ ■